These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 21963621)

  • 1. Mesenchymal stromal cells: a new tool against graft-versus-host disease?
    Baron F; Storb R
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):822-40. PubMed ID: 21963621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
    Zhao L; Chen S; Yang P; Cao H; Li L
    Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.
    Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease.
    Ringdén O; Gustafsson B; Sadeghi B
    Front Immunol; 2020; 11():567210. PubMed ID: 33193339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
    Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
    Front Immunol; 2019; 10():619. PubMed ID: 31001253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.
    Morata-Tarifa C; Macías-Sánchez MDM; Gutiérrez-Pizarraya A; Sanchez-Pernaute R
    Stem Cell Res Ther; 2020 Feb; 11(1):64. PubMed ID: 32070420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
    Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
    Front Immunol; 2022; 13():959658. PubMed ID: 36189324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.
    Mielcarek M; Storb R; Georges GE; Golubev L; Nikitine A; Hwang B; Nash RA; Torok-Storb B
    Biol Blood Marrow Transplant; 2011 Feb; 17(2):214-25. PubMed ID: 20816818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of treatment with DLA-identical or unrelated mesenchymal stromal cells in DLA-identical canine bone marrow transplantation.
    Kornblit B; Leisenring WM; Santos EB; Storb R; Sandmaier BM
    Chimerism; 2013; 4(3):95-101. PubMed ID: 23723082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
    Ringdén O; Moll G; Gustafsson B; Sadeghi B
    Front Immunol; 2022; 13():839844. PubMed ID: 35371003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mesenchymal stem cells for treatment of graft-versus-host disease].
    Najima Y
    Rinsho Ketsueki; 2017; 58(12):2440-2449. PubMed ID: 29332881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation.
    Min CK; Kim BG; Park G; Cho B; Oh IH
    Bone Marrow Transplant; 2007 May; 39(10):637-45. PubMed ID: 17369865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimerism of bone marrow mesenchymal stem/stromal cells in allogeneic hematopoietic cell transplantation: is it clinically relevant?
    Miura Y; Yoshioka S; Yao H; Takaori-Kondo A; Maekawa T; Ichinohe T
    Chimerism; 2013; 4(3):78-83. PubMed ID: 23880502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
    Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
    Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel study on the immunomodulatory effect of umbilical cord derived mesenchymal stem cells pretreated with traditional Chinese medicine Asarinin.
    He H; Yang T; Li F; Zhang L; Ling X
    Int Immunopharmacol; 2021 Nov; 100():108054. PubMed ID: 34492537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Kallekleiv M; Larun L; Bruserud Ø; Hatfield KJ
    Cytotherapy; 2016 Feb; 18(2):172-85. PubMed ID: 26794711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.